This article has Open Peer Review reports available.
Oxidative stress level is not associated with survival in terminally ill cancer patients: a preliminary study
© Yeom et al.; licensee BioMed Central Ltd. 2014
Received: 30 November 2013
Accepted: 19 March 2014
Published: 21 March 2014
While cancer patients have higher oxidative stress (OS) and lower antioxidant activity, evidence for the association of these parameters with survival in patients with terminally ill cancer is lacking.
We followed 65 terminal cancer patients prospectively. We assessed their performance status, some symptoms, and serum levels of vitamin C and OS level. The Gehan’s generalized Wilcoxon test was used to examine the association between survival times and variables.
Subjects’ performance status was very poor and they had a high level of OS and a low level of vitamin C. No significant association of these two parameters with survival time was noted (p-value, 0.637 for high OS and 0.240 for low vitamin C). Poor performance status was independently related to high OS status after adjusting for potential confounders (adjusted OR, 4.45; p-value, 0.031).
In this study, OS was not associated with survival of terminally ill cancer patients and its prognostic role requires further study.
Prognostication of life expectancy is a significant clinical commitment for clinicians involved in oncology, especially in hospice-palliative care settings. Accurate estimates provide patients and families with a time frame in which to emotionally and financially prepare for the death . However, studies on survival prediction in terminally ill patients suggest that it is very difficult to make an accurate prognosis and even experienced palliative care physicians find such a prediction difficult .
Patients with malignant tumors have higher oxidative stress (OS) by tumor growth itself and/or increased systemic inflammatory response [3, 4]. OS is defined as a state in which the level of toxic reactive oxygen intermediates overcomes the endogenous antioxidant defenses. OS can therefore result from either excess production of free radicals or depletion of antioxidant defenses . Meanwhile, vitamin C is a well-known antioxidant that humans are unable to synthesize and must obtain from an exogenous source. Reductions in vitamin C intake are associated with illness, hospitalization, and institutionalization. A population-based cohort study with breast cancer patients demonstrated that women consuming the highest tertile of vitamin C were significantly more likely to survive compared to those in the lowest tertile of intake . Furthermore, a recent study reported that patients with low plasma levels of vitamin C have a significantly worse prognosis than patients with normal levels .
While a few studies have shown a correlation between survival and either serum vitamin C level or OS in cancer patients, direct evidence for this association in terminally ill cancer patients is lacking. Therefore, we aimed primarily to determine the relationship between survival and serum vitamin C or OS level in terminally-ill cancer patients. In addition, even if not associated with survival, we investigated whether these specific laboratory findings were connected with performance status (PS).
Design and subjects
Data on demographics and clinical information were collected by an experienced palliative care team of physicians and registered nurses: included information were age, sex, cancer site, Eastern Cooperative Oncology Group (ECOG) performance status, palliative prognostic score , presence of fever and anorexia, and evidence of infection. The ECOG performance status is an observer-rated scale of patient physical ability using numbers ranging from 0 (able to carry out all normal activities) to 4 (completely disabled) . Anorexia was defined as less than five spoons per meal (about one-third amount of routine meal). Patients also provided clinical information on average pain score by numerical rating scale and presence of some symptoms (dysphagia and dyspnea on exertion). Dysphagia and dyspnea were determined by the following yes-no question: “In the past 24 h, have you been difficult to swallow/short of breath on exertion?” Survival times were measured from the date of enrollment in the study.
In all subjects, blood samples were obtained from venipuncture of an antecubital vein. Blood samples were used to measure complete blood cell count (white blood cell and lymphocyte proportion), liver function (albumin and total bilirubin), uric acid, creatinine, lactate dehydrogenase (LDH) and C-reactive protein (CRP). We determined oxidative stress levels by the Free Oxygen Radical Test (FORT; Free Oxygen Radicals Monitor Plus, Callegari, Italy), a colorimetric assay based on the ability of transition metals, such as iron, to catalyze the breakdown of hydroperoxides (ROOH) into derivative radicals, according to Fenton’s reaction. Results are expressed as FORT units (U.F.), where 1 U.F. corresponds to 0.26 mg/l H2O2. The assay is completed in 6 minutes. Data suggest that FORT can satisfactorily assess the level of oxidative radicals in whole blood . We also measured serum vitamin C concentration by High Performance Liquid Chromatography, which has been validated as a rapid an specific measurement of vitamin C .
Data are presented as median (interquartile range) or number (%). We dichotomized variables and chose a cut-off point at the reference range or median values. To examine the association between survival times and variables, and we used Gehan’s generalized Wilcoxon test. We evaluated the associations between OS and PS using the logistic regression model. We used SPSS statistical package version 16.02 (SPSS, Chicago, IL, USA). P values less than 0.05 were considered significant.
Patient population and clinical characteristics
Characteristics of study patients (N = 65)
Survival timeb, days
Primary cancer site
ECOG performance status
Dyspnea on exertion
Uncontrolled pain (NRS ≥ 4)
Palliative prognostic score
Laboratory findingsa (reference range)
Bilirubin, mg/dL (0.2-1.2)
Creatinine, mg/dL (0.5-1.2)
Lactate dehydrogenase, U/L (200–485)
Uric acid, mg/dL (2.5-8.3)
Albumin, g/dL (3.5-5.2)
C-reactive protein, mg/dL (< 0.5)
Vitamin C, μg/mL (1.9-15.0)
0.44 (< 0.03-0.89)
Oxidative stressc, U.F. (160–310)
Prognostic factors on survival
Patient characteristics and univariate survival analysis
No. of patients
HR (95% CI)
Primary tumor site (any type)
Palliative prognostic score
Lactate dehydrogenase (U/L)
Uric acid (mg/dL)
C-reactive protein (mg/dL)
Serum vitamin C (μg/mL)
Oxidative stress (U.F.)
OS and PS
Oxidative stress status and baseline clinical characteristics
Higher oxidative stress (≥ median, 412.9 U.F.)
Aged (> 65 yrs)
Palliative prognostic score (≥ 7.5a)
Dyspnea on exertion
Uncontrolled pain (NRS ≥ 4)
Elevated lactate dehydrogenase
Higha C-reactive protein
Lowa vitamin C
Performance (ECOG = 4)
The idea of being able to prognosticate from the results of a simple blood test is very appealing to palliative care physicians. The need for a blood sample must also be weighed against the likely clinical advantage for the individual patient. Biologic parameters have not been as widely investigated as clinical parameters in terminally ill cancer patients , and a more accurate evaluation of these variables in relation to prognosis is undoubtedly warranted.
To our knowledge, this is a rare study that investigated the clinical effectiveness of measuring serum vitamin C or OS in terminally ill cancer patients. In this study, the main findings were that: (i) these parameters had no prognostic significance; (ii) serum OS level was associated with PS of patients; and (iii) serum vitamin C level was not correlated with OS level.
It is well known that cancer patients are characterized by higher levels of OS markers and lower levels of serum vitamin C than healthy controls; there is a scarcity of literature addressing the association with survival of advanced cancer patients at the end of life . Mayland et al.  reported that low plasma vitamin C concentrations were associated with shorter survival in terminally ill cancer patients. But those findings were not confirmed by multivariate analysis and they did not address the level of OS, which could be a predictor of cancer-specific survival . In the current study, we were unable to demonstrate prognostic significance of serum vitamin C or OS on survival. The lack of significance could be due to (i) true negative finding: these parameters are not helpful to discriminate the patients with a short survival, or (ii) false negative findings: small sample size or artificial cutoff value.
While several studies have shown that OS level was associated with the cancer patient’s PS [15, 16], little work has been done in terminally ill cancer patients. The distressing symptoms experienced by cancer patients may be related to OS: these symptoms may also lead to the patients’ poor PS . Especially in the terminal stage, deranged energy metabolism, which may account for symptoms such as nausea/vomiting, anorexia and cachexia that cause malnutrition, could accelerate the production of free radicals. Additionally, a previous study reported that the OS levels decreased significantly after antioxidant treatment regardless of patient’s PS , although these reductions might not lead to performance improvement [17, 18]. Further well-controlled clinical trials are needed to clarify the clinical effect of intervention.
Based on the complex situation caused by an imbalance between OS and antioxidant ability, it is plausible that separate assessments of OS and antioxidant status do not provide sufficient information . For that reason we assessed both parameters, but could not find any correlation between them. With healthy adults, Block et al.  found that serum vitamin C was inversely correlated with biomarkers of OS even after adjusting for other antioxidants. The antioxidant system counteracts OS constantly and prevents certain damage by scavenging reactive oxygen species , but this balance may be limited to healthy subjects. As the disease progresses and death nears, OS levels escalate markedly without linear reduction of antioxidant capacity. Therefore, a higher OS level may have more influence on the outcome for terminal cancer patients than decreased antioxidant biomarkers. Two recent studies by Vera-Ramirez et al. with breast cancer patients back this up. In non-metastatic breast cancer patients, they demonstrated that both antioxidant capacity and OS biomarkers had significant association with survival rate . In contrast, in a metastatic setting with the same protocol, only OS parameters significantly influenced the survival rates of the patients .
The current study contains some limitations that should be acknowledged. First, this sample of patients is too small. Large-scale studies are needed to confirm our findings, because short survival time is unavoidable when dealing with subjects in a hospice setting. Second, by using a single measurement, we have likely underestimated the association of serum vitamin C level and OS status with survival. Third, we only adjusted for confounders statistically and could not exclude acute inflammatory conditions or anti-inflammatory medication users, which can affect OS . However, terminally ill cancer patients are very susceptible to infection , and they have also taken multiple drugs due to a wide variety of symptoms and associated comorbid conditions . Finally, some symptoms such as anorexia, dysphagia and dyspea on exertion were not evaluated by a validated symptom assessment tool.
Our study demonstrates that OS status was not associated with survival of cancer patients at the very end of life. Further studies are needed in order to elucidate the relationship between survival and OS.
This study was supported by the Korean Association for Vitamin Research. The sponsor had no role in this study.
- Yun YH, Heo DS, Heo BY, Yoo TW, Bae JM, Ahn SH: Development of terminal cancer prognostic score as an index in terminally ill cancer patients. Oncol Rep. 2001, 8 (4): 795-800.PubMedGoogle Scholar
- Glare PA, Sinclair CT: Palliative medicine review: prognostication. J Palliat Med. 2008, 11 (1): 84-103.View ArticlePubMedGoogle Scholar
- Toyokuni S, Okamoto K, Yodoi J, Hiai H: Persistent oxidative stress in cancer. FEBS Lett. 1995, 358 (1): 1-3.View ArticlePubMedGoogle Scholar
- Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB: Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic Biol Med. 2010, 49 (11): 1603-1616.View ArticlePubMedPubMed CentralGoogle Scholar
- McCall MR, Frei B: Can antioxidant vitamins materially reduce oxidative damage in humans?. Free Radic Biol Med. 1999, 26 (7–8): 1034-1053.View ArticlePubMedGoogle Scholar
- McEligot AJ, Largent J, Ziogas A, Peel D, Anton-Culver H: Dietary fat, fiber, vegetable, and micronutrients are associated with overall survival in postmenopausal women diagnosed with breast cancer. Nutr Cancer. 2006, 55 (2): 132-140.View ArticlePubMedGoogle Scholar
- Mayland CR, Bennett MI, Allan K: Vitamin C deficiency in cancer patients. Palliat Med. 2005, 19 (1): 17-20.View ArticlePubMedGoogle Scholar
- Pirovano M, Maltoni M, Nanni O, Marinari M, Indelli M, Zaninetta G, Petrella V, Barni S, Zecca E, Scarpi E, Labianca R, Amadori D, Luporini G: A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manage. 1999, 17 (4): 231-239.View ArticlePubMedGoogle Scholar
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982, 5 (6): 649-655.View ArticlePubMedGoogle Scholar
- Palmieri B, Sblendorio V: Current status of measuring oxidative stress. Methods Mol Biol. 2010, 594: 3-17.View ArticlePubMedGoogle Scholar
- Tessier F, Birlouez-Aragon I, Tjani C, Guilland JC: Validation of a micromethod for determining oxidized and reduced vitamin C in plasma by HPLC-fluorescence. Int J Vitam Nutr Res. 1996, 66 (2): 166-170.PubMedGoogle Scholar
- Vigano A, Dorgan M, Buckingham J, Bruera E, Suarez-Almazor ME: Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med. 2000, 14 (5): 363-374.View ArticlePubMedGoogle Scholar
- Mahdavi R, Faramarzi E, Seyedrezazadeh E, Mohammad-Zadeh M, Pourmoghaddam M: Evaluation of oxidative stress, antioxidant status and serum vitamin C levels in cancer patients. Biol Trace Elem Res. 2009, 130 (1): 1-6.View ArticlePubMedGoogle Scholar
- Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Tortosa MC, Ramirez-Tortosa CL, Granados-Principal S, Lorente JA, Quiles JL: Oxidative stress status in metastatic breast cancer patients receiving palliative chemotherapy and its impact on survival rates. Free Radic Res. 2012, 46 (1): 2-10.View ArticlePubMedGoogle Scholar
- Mantovani G, Maccio A, Madeddu C, Mura L, Massa E, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L: Reactive oxygen species, antioxidant mechanisms and serum cytokine levels in cancer patients: impact of an antioxidant treatment. J Cell Mol Med. 2002, 6 (4): 570-582.View ArticlePubMedGoogle Scholar
- Mantovani G, Maccio A, Madeddu C, Mura L, Gramignano G, Lusso MR, Massa E, Mocci M, Serpe R: Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med (Berl). 2003, 81 (10): 664-673.View ArticleGoogle Scholar
- Mantovani G, Madeddu C, Maccio A, Gramignano G, Lusso MR, Massa E, Astara G, Serpe R: Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev. 2004, 13 (10): 1651-1659.PubMedGoogle Scholar
- Maccio A, Madeddu C, Gramignano G, Mulas C, Floris C, Sanna E, Cau MC, Panzone F, Mantovani G: A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol. 2012, 124 (3): 417-425.View ArticlePubMedGoogle Scholar
- Hristozov D, Gadjeva V, Vlaykova T, Dimitrov G: Evaluation of oxidative stress in patients with cancer. Arch Physiol Biochem. 2001, 109 (4): 331-336.View ArticlePubMedGoogle Scholar
- Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Caan B, Packer L: Factors associated with oxidative stress in human populations. Am J Epidemiol. 2002, 156 (3): 274-285.View ArticlePubMedGoogle Scholar
- Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006, 160 (1): 1-40.View ArticlePubMedGoogle Scholar
- Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Tortosa MC, Ramirez-Tortosa CL, Granados-Principal S, Fernandez-Navarro M, Lorente JA, Quiles JL: Does chemotherapy-induced oxidative stress improve the survival rates of breast cancer patients?. Antioxid Redox Signal. 2011, 15 (4): 903-909.View ArticlePubMedGoogle Scholar
- Marwali MR, Hu CP, Mohandas B, Dandapat A, Deonikar P, Chen J, Cawich I, Sawamura T, Kavdia M, Mehta JL: Modulation of ADP-induced platelet activation by aspirin and pravastatin: role of lectin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and inside-out integrin signaling. J Pharmacol Exp Ther. 2007, 322 (3): 1324-1332.View ArticlePubMedGoogle Scholar
- Chanock S: Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am. 1993, 7 (4): 771-793.PubMedGoogle Scholar
- McLean S, Sheehy-Skeffington B, O’Leary N, O’Gorman A: Pharmacological management of co-morbid conditions at the end of life: is less more?. Ir J Med Sci. 2013, 182 (1): 107-112.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-684X/13/14/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.